research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
Search
for
Sort by
Research
480-510 / 1000+ results research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Hair graying and loss induced by imatinib mesylate
A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
Upadacitinib effectively treats psoriasiform eczema and some related conditions.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature
Stopping TNFα inhibitors can help children regrow hair lost due to the medication.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research A 5α-reductase inhibitor, finasteride, increases differentiation and proliferation of embryonal carcinoma cell-derived-neural cells
research Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata
Topical tofacitinib is effective and safe for treating alopecia areata.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Sorafenib-induced Facial Acneiform Eruption
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
Iressa often causes skin issues like acne and dryness in lung cancer patients.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Management of a Refractory EIF3E-RSPO2 Fusion Positive Pilomatrical Cancer Patient with Encyclopedic Tumor Analysis Guided Treatment
Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines
The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Author reply
Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
research Alopecia areata: from pathophysiology to therapeutic innovation
JAK inhibitors are effective treatments for alopecia areata.
research Erlotinib induced acneiform eruption: A case report
Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.